Published in Immunol Cell Biol on September 06, 2011
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol (2013) 1.05
Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators. Vaccines (Basel) (2014) 0.84
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One (2013) 0.81
Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One (2014) 0.79
Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation. Sci Rep (2015) 0.79
CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int (2013) 0.79
In vivo and in vitro characterization of the immune stimulating activity of the Neisserial porin PorB. PLoS One (2013) 0.78
Development of a universal CTL-based vaccine for influenza. Bioengineered (2013) 0.78
A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates. Sci Rep (2016) 0.77
QS-21 enhances the early antibody response to oil adjuvant foot-and-mouth disease vaccine in cattle. Clin Exp Vaccine Res (2016) 0.75
Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines. PLoS Pathog (2016) 0.75
The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIX(TM) Adjuvant. Vaccines (Basel) (2016) 0.75
Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Dendritic cells and the control of immunity. Nature (1998) 56.54
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
Development of monocytes, macrophages, and dendritic cells. Science (2010) 12.86
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 9.67
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Mice lacking MHC class II molecules. Cell (1991) 6.25
Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science (2003) 5.00
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med (1996) 4.70
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol (2009) 4.51
The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol (1981) 3.99
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 3.98
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 3.59
Inflammasomes: guardians of cytosolic sanctity. Immunol Rev (2009) 3.58
Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol (2006) 3.57
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol (2005) 3.47
Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer (2005) 3.31
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol (2004) 2.87
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 2.63
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61
Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood (2000) 2.45
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol (2007) 2.22
Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol (2004) 2.10
Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood (2003) 2.05
Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol (2003) 1.63
Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol (2005) 1.40
Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol (2006) 1.36
Mechanism of action of licensed vaccine adjuvants. Vaccine (2009) 1.34
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines (2007) 1.20
In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood (2002) 1.16
Regulatory T cells and immune tolerance to tumors. Immunol Res (2010) 1.15
Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity. J Biol Chem (2003) 1.14
ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol (2009) 1.08
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol (2009) 1.07
Probing in vivo dendritic cell functions by conditional cell ablation. Immunol Cell Biol (2008) 1.02
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer (2011) 1.02
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res (2004) 1.00
LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun (2011) 0.96
A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther (2010) 0.91
Kinetics of macrophage recruitment and turnover in peritoneal inflammatory exudates induced by Salmonella or thioglycollate broth. J Leukoc Biol (1986) 0.89
Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov (2009) 0.82
ISCOM based vaccines for cancer immunotherapy. Vaccine (2004) 0.76
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science (2003) 5.00
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 3.98
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity (2009) 3.66
Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol (2009) 3.63
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 3.59
Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol (2006) 3.57
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54
The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol (2011) 3.44
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A (2006) 3.19
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat Immunol (2006) 3.09
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 2.84
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Tumor necrosis factor: an apoptosis JuNKie? Cell (2004) 2.64
Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity (2008) 2.62
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol (2013) 2.48
Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol (2008) 2.44
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity (2013) 2.37
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood (2002) 2.30
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol (2012) 2.14
NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell (2011) 2.13
Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood (2003) 2.05
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 1.99
New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. Vaccine (2013) 1.96
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity (2009) 1.85
Loss of Bim increases T cell production and function in interleukin 7 receptor-deficient mice. J Exp Med (2004) 1.83
Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. J Immunol (2007) 1.75
Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol (2010) 1.75
Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci U S A (2008) 1.73
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol (2004) 1.70
The transcription factor T-bet is essential for the development of NKp46+ innate lymphocytes via the Notch pathway. Nat Immunol (2013) 1.70
B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med (2012) 1.65
Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol (2003) 1.63
An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature (2012) 1.60
TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 1.59
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol (2005) 1.58
Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol (2009) 1.55
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.55
Identification of the earliest NK-cell precursor in the mouse BM. Blood (2011) 1.54
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine (2012) 1.49
Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1. Biochem J (2013) 1.45
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 1.44
Id2 expression delineates differential checkpoints in the genetic program of CD8α+ and CD103+ dendritic cell lineages. EMBO J (2011) 1.41
Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood (2009) 1.40
Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesis. J Exp Med (2003) 1.39
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood (2004) 1.39
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem (2005) 1.38
TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell (2012) 1.34
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34
Can allodynic migraine patients be identified interictally using a questionnaire? Neurology (2005) 1.31
TCF-1 controls ILC2 and NKp46+RORγt+ innate lymphocyte differentiation and protection in intestinal inflammation. J Immunol (2013) 1.29
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 1.27
Cutting edge: precursor frequency affects the helper dependence of cytotoxic T cells. J Immunol (2002) 1.27
The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 1.24
Differential requirement for Nfil3 during NK cell development. J Immunol (2014) 1.21
Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. Immunol Cell Biol (2007) 1.21
ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines (2007) 1.20
Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One (2012) 1.19
Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A (2006) 1.18